keyword
MENU ▼
Read by QxMD icon Read
search

whole brain radiotherapy

keyword
https://www.readbyqxmd.com/read/29222306/therapy-of-primary-cns-lymphoma-role-of-intensity-radiation-and-novel-agents
#1
REVIEW
Andrés José María Ferreri
Primary central nervous system (CNS) lymphomas represent a subgroup of malignancies with specific characteristics, an aggressive course, and unsatisfactory outcome in contrast with other lymphomas comparable for tumor burden and histological type. Despite the high sensitivity to conventional chemotherapy and radiotherapy, remissions are frequently short lasting. Treatment efficacy is limited by several factors, including the biology and microenvironment of this malignancy and the "protective" effect of the blood-brain barrier, which limits the access of most drugs to the CNS...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29222214/treating-patients-with-brain-metastases-has-evolved-scalp-sparing-hippocampal-avoidance-whole-brain-radiotherapy-with-simultaneous-integrated-boost
#2
Irfan Ahmad, Kundan Singh Chufal, Chandi Prasad Bhatt, Sandeep Rathour
No abstract text is available yet for this article.
December 7, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29209838/imp3-expression-in-nsclc-brain-metastases-demonstrates-its-role-as-a-prognostic-factor-in-non-neuroendocrine-phenotypes
#3
Alessandro Del Gobbo, Annamaria Morotti, Anna Eleonora Colombo, Valentina Vaira, Giulia Ercoli, Chiara Pesenti, Eleonora Bonaparte, Elena Guerini-Rocco, Andrea Di Cristofori, Marco Locatelli, Alessandro Palleschi, Stefano Ferrero
Brain metastases from NSCLC are associated with a poor prognosis, and local radiotherapy is the most effective therapeutic strategy. The oncofetal protein IMP3 has been studied extensively, and evidence suggests that its expression is related to shorter overall survival and a more aggressive phenotype in solid malignancies. Here, the prognostic role of IMP3 was investigated in a cohort of patients with NSCLC brain metastases in correlation with survival and tumor histotype. A series of 42 NSCLC brain metastases samples was analyzed by tissue microarray and immunohistochemical staining for IMP3...
December 1, 2017: Medical Oncology
https://www.readbyqxmd.com/read/29187495/outcome-evaluation-of-her2-breast-cancer-patients-with-limited-brain-metastasis
#4
Federico Pessina, Pierina Navarria, Luca Cozzi, Davide Franceschini, Stefano Tomatis, Elena Clerici, Anna Maria Ascolese, Fiorenza DE Rose, Lorenzo Bello, Giovanna Masci, Armando Santoro, Marta Scorsetti
BACKGROUND/AIM: To appraise the outcome of limited brain metastasis (BMs) from HER2 breast cancer. PATIENTS AND METHODS: The study cohort included sixty-six patients Treatments consisted of surgery followed by radiotherapy (RT), or radiosurgery (SRS/HSRS) or whole brain radiotherapy (WBRT). RESULTS: Surgery followed by RT was performed in 25.8% of patients, SRS/HSRS alone in 48.5%, and WBRT alone in 25.7%. The median follow-up time was 23...
December 2017: Anticancer Research
https://www.readbyqxmd.com/read/29185589/bevacizumab-and-gefitinib-enhanced-whole-brain-radiation-therapy-for-brain-metastases-due-to-non-small-cell-lung-cancer
#5
R F Yang, B Yu, R Q Zhang, X H Wang, C Li, P Wang, Y Zhang, B Han, X X Gao, L Zhang, Z M Jiang
Non-small-cell lung cancer (NSCLC) patients who experience brain metastases are usually associated with poor prognostic outcomes. This retrospective study proposed to assess whether bevacizumab or gefitinib can be used to improve the effectiveness of whole brain radiotherapy (WBRT) in managing patients with brain metastases. A total of 218 NSCLC patients with multiple brain metastases were retrospectively included in this study and were randomly allocated to bevacizumab-gefitinib-WBRT group (n=76), gefitinib-WBRT group (n=77) and WBRT group (n=75)...
November 17, 2017: Brazilian Journal of Medical and Biological Research, Revista Brasileira de Pesquisas Médicas e Biológicas
https://www.readbyqxmd.com/read/29172778/response-to-afatinib-in-treatment-na%C3%A3-ve-patients-with-advanced-mutant-epidermal-growth-factor-receptor-lung-adenocarcinoma-with-brain-metastases
#6
Shih-Hong Li, Chien-Ying Liu, Ping-Chih Hsu, Yueh-Fu Fang, Chun-Chieh Wang, Kuo-Chin Kao, Li-Chuan Tseng, Cheng-Ta Yang
BACKGROUND: Brain metastases are observable in 20-40% of non-small cell lung cancer patients, but standard treatments for such metastases may be intolerable to some. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were found to be effective against mutant-EGFR lung adenocarcinomas, but data regarding their effectiveness, especially for the second-generation EGFR-TKI afatinib, is limited. This study compared key outcomes for afatanib monotherapy versus afatinib combined with whole-brain radiotherapy (WBRT) in treatment-naïve lung adenocarcinoma patients harboring EGFR mutations...
December 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29170039/-delineation-of-the-surgical-bed-of-operated-brain-metastases-treated-with-adjuvant-stereotactic-irradiation-a-review
#7
A Keller, G Noël, D Antoni
Stereotactic radiotherapy of the surgical bed of brain metastases is a technique that comes supplant indications of adjuvant whole brain radiotherapy after surgery. After a growing number of retrospective studies, a phase III trial has been presented and validated this indication. However, several criteria such as the dose, the fractionation, the use of a margin and definition of volumes remain to be defined. Our study consisted in making a literature review in order to provide a guideline of delineation of surgical beds of brain metastases, as well as the different modalities of their implementation process...
November 20, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/29161348/multi-institutional-competing-risks-analysis-of-distant-brain-failure-and-salvage-patterns-after-upfront-radiosurgery-without-whole-brain-radiotherapy-for-brain-metastasis
#8
E McTyre, D Ayala-Peacock, J Contessa, C Corso, V Chiang, C Chung, J Fiveash, M Ahluwalia, R Kotecha, S Chao, A Attia, A Henson, J Hepel, S Braunstein, M Chan
Background: In this study we use a competing risks analysis to assess factors predictive of early salvage whole brain radiotherapy (WBRT) and early death after upfront stereotactic radiosurgery (SRS) alone for brain metastases in an attempt to identify populations that benefit less from upfront SRS. Patients and methods: Patients from eight academic centers were treated with SRS for brain metastasis. Competing risks analysis was performed for distant brain failure (DBF) vs...
November 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29145292/recurrent-spinal-primitive-neuroectodermal-tumor-with-brain-and-bone-metastases-a-case-report
#9
Frank Chen, Shyh-Shin Chiou, Sheng-Fung Lin, Ann-Shung Lieu, Yi-Ting Chen, Chih-Jen Huang
RATIONALE: Primary spinal primitive neuroectodermal tumor (PNET) is relatively rare in all age groups, and the prognosis in most cases of spinal PNETs appears to be poor, with a median patient survival of 1 to 2 years. We present a case with recurrent spinal PNET with brain and bone metastases that was successfully treated by multimodality treatment. PATIENT CONCERNS: A 14-year-old teenage girl had suffered from progressive left upper back pain with bilateral lower legs weakness and numbness for 1 year...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29139010/radiobiology-and-radiotherapy-of-brain-metastases
#10
Anuradha Thiagarajan, Yoshiya Yamada
Brain metastases are the most common intracranial tumors in adults, accounting for more than 50% of all such cases. The approach to and management of brain metastases have evolved significantly in recent years due to several reasons. These include advances in neurosurgical and radiotherapeutic techniques, improved systemic therapy options offering better systemic and intracranial disease control and prolongation of survival as a result of these improvements, making side-effects of proposed therapies (e.g. neurocognitive decline from whole brain radiotherapy) an important consideration...
November 14, 2017: Clinical & Experimental Metastasis
https://www.readbyqxmd.com/read/29131101/outcomes-and-prognostic-factors-in-pediatric-oligodendroglioma-a-population-based-study
#11
Nicholas J Goel, Kalil G Abdullah, Shih-Shan Lang
BACKGROUND/AIMS: Pediatric oligodendroglioma (pODG) is a rare primary brain tumor that remains poorly understood. Demographics, outcomes, and prognostic factors were analyzed in 346 pODG cases from the Surveillance, Epidemiology, and End Results database. METHODS: Gender, race, age, tumor location, tumor size, tumor grade, extent of resection, and use of radiotherapy were evaluated with respect to overall survival (OS) by univariate and multivariate analysis. These factors were assessed in the pediatric cohort and 5,753 adult oligodendroglioma cases for comparison...
November 2, 2017: Pediatric Neurosurgery
https://www.readbyqxmd.com/read/29124419/a-systematic-review-to-assess-the-management-of-patients-with-cerebral-metastases-secondary-to-colorectal-cancer
#12
REVIEW
I L Silva, M Iskandarani, A Hotouras, J Murphy, C Bhan, B Adada, S D Wexner
BACKGROUND: Colorectal cancer (CRC) rarely metastasizes to the brain. The incidence of cerebral metastases (CM) is estimated between 1 and 3%. Given the improved survival from advanced CRC as a result of surgical and oncological advances, it is anticipated that the incidence of patients with CM from CRC will rise over the next few years. The aim of this article was to systematically review the treatment options and outcome of patients with CM from CRC. METHODS: PubMed and Medline databases were examined using the search words or MESH headings "colorectal" "cancer/carcinoma/adenocarcinoma", "cerebral"/"brain" and "metastases/metastasis"...
November 9, 2017: Techniques in Coloproctology
https://www.readbyqxmd.com/read/29117865/correction-to-improved-plan-quality-with-automated-radiotherapy-planning-for-whole-brain-with-hippocampus-sparing-a-comparison-to-the-rtog-0933-trial
#13
J Krayenbuehl, M Di Martino, M Guckenberger, N Andratschke
In the original publication [1] figure legends 2 and 4 have been swapped. The original article was updated to rectify this error.
November 8, 2017: Radiation Oncology
https://www.readbyqxmd.com/read/29112734/memantine-prevents-acute-radiation-induced-toxicities-at-hippocampal-excitatory-synapses
#14
Joseph G Duman, Jeffrey Dinh, Wei Zhou, Henry Cham, Vasilis C Mavratsas, Matea Paveškovic, Shalaka Mulherkar, Susan L McGovern, Kimberley F Tolias, David R Grosshans
Background: Memantine has shown clinical utility in preventing radiation-induced cognitive impairment, but the mechanisms underlying its protective effects remain unknown. We hypothesized that abnormal glutamate signaling causes radiation-induced abnormalities in neuronal structure and that memantine prevents synaptic toxicity. Methods: Hippocampal cultures expressing eGFP were irradiated or sham-treated and their dendritic spine morphology assessed at acute (minutes) and later (days) times using high-resolution confocal microscopy...
November 2, 2017: Neuro-oncology
https://www.readbyqxmd.com/read/29089533/proton-minibeam-radiation-therapy-spares-normal-rat-brain-long-term-clinical-radiological-and-histopathological-analysis
#15
Yolanda Prezado, Gregory Jouvion, David Hardy, Annalisa Patriarca, Catherine Nauraye, Judith Bergs, Wilfredo González, Consuelo Guardiola, Marjorie Juchaux, Dalila Labiod, Remi Dendale, Laurène Jourdain, Catherine Sebrie, Frederic Pouzoulet
Proton minibeam radiation therapy (pMBRT) is a novel strategy for minimizing normal tissue damage resulting from radiotherapy treatments. This strategy partners the inherent advantages of protons for radiotherapy with the gain in normal tissue preservation observed upon irradiation with narrow, spatially fractionated beams. In this study, whole brains (excluding the olfactory bulb) of Fischer 344 rats (n = 16) were irradiated at the Orsay Proton Therapy Center. Half of the animals received standard proton irradiation, while the other half were irradiated with pMBRT at the same average dose (25 Gy in one fraction)...
October 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29070115/-curative-efficacy-of-high-dose-mtx-combined-with-rituxan-for-treatment-primary-cns-lymphoma
#16
Kun Mou, Wei-Wei Gu, Cui-Hua Gu, Jiu-De Qi
OBJECTIVE: To explore the curative efficacy of methotrexate(MTX) combined with rituxan for treating patients with primary central nervous system(CNS) lymphoma. METHODS: One hundred patients with primary CNS lymphoma in our hospital were randomly divided into targeted treatment group(50 cases) and traditional treatment group (50 cases). Targeted treatment group adopted the therapy of high-dose methotrexate combined with rituxan, the traditional treatment group adopted the high-dose methotrexate combined with whole brain radiotherapy...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29069502/predicting-prognosis-of-short-survival-time-after-palliative-whole-brain-radiotherapy
#17
Kazunari Miyazawa, Naoto Shikama, Shohei Okazaki, Tadaaki Koyama, Takao Takahashi, Shingo Kato
Using existing prognostic models, including the Graded Prognostic Assessment (GPA), it is difficult to identify patients with brain metastases (BMs) who are not likely to survive 2 months after whole-brain radiotherapy (WBRT). The purpose of this study was to identify a subgroup of patients who would not benefit clinically from WBRT. We retrospectively reviewed the records of 111 patients with BMs who were ineligible for surgery or stereotactic irradiation and who underwent WBRT between March 2013 and April 2016...
October 24, 2017: Journal of Radiation Research
https://www.readbyqxmd.com/read/29068981/human-herpes-virus-8-unrelated-primary-effusion-lymphoma-like-lymphoma-presenting-with-cardiac-tamponade-a-case-report
#18
Hee-Jun Kim, Kyoungyul Lee, Chang-Hwan Yoon, Soo-Mee Bang
RATIONALE: Primary effusion lymphoma (PEL) is a rare disease of lymphomatous effusion in the body cavities in the absence of detectable mass and lymphadenopathy. PEL is predominantly related to the immunosuppressed patients infected with human herpes virus 8 (HHV-8). PEL-like lymphoma is negative for HHV-8 and human immunodeficiency virus (HIV) unlike PEL. The pathogenesis and prognosis of PEL-like lymphoma are unclear and there is no established treatment yet. PATIENT CONCERNS: A 73-year-old male patient was admitted for evaluation of dyspnea on exertion with 1-week duration...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29063053/management-of-breast-cancer-brain-metastases-focus-on-human-epidermal-growth-factor-receptor-2-positive-breast-cancer
#19
REVIEW
Peng Yuan, Song-Lin Gao
After the introduction of trastuzumab, a monoclonal antibody that binds to human epidermal growth factor receptor 2 (HER2), the overall survival (OS) among patients with HER2-positive breast cancer has been substantially improved. However, among these patients, the incidence of brain metastases (BM) has been increasing and an increased proportion of them have died of intracranial progression, which makes HER2-positive breast cancer brain metastases (BCBM) a critical issue of concern. For local control of limited BM, stereotactic radiosurgery (SRS) and surgical resection are available modalities with different clinical indications...
March 25, 2017: Chronic diseases and translational medicine
https://www.readbyqxmd.com/read/29054815/whole-brain-radiotherapy-or-autologous-stem-cell-transplantation-as-consolidation-strategies-after-high-dose-methotrexate-based-chemoimmunotherapy-in-patients-with-primary-cns-lymphoma-results-of-the-second-randomisation-of-the-international-extranodal-lymphoma
#20
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, Christopher P Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, Alberto Fabbri, Valter Torri, Eleonora Minacapelli, Monica Falautano, Fiorella Ilariucci, Achille Ambrosetti, Alexander Roth, Claire Hemmaway, Peter Johnson, Kim M Linton, Tobias Pukrop, Jette Sønderskov Gørløv, Monica Balzarotti, Georg Hess, Ulrich Keller, Stephan Stilgenbauer, Jens Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Alessandro Levis, Stefan W Krause, Hans J Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, Francesco Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus
BACKGROUND: The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested...
November 2017: Lancet Haematology
keyword
keyword
100499
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"